Study of Sleep Problems and Cognitive Decline in Adults Aged 50 to 85 with Mild Alzheimers Disease and APOEb54 Risk

What this Trial Is About

Alzheimers disease AD involves a gradual loss of memory and thinking skills, linked to the buildup of beta-amyloid peptides in the brain. Researchers are investigating whether sleep problems are connected to cognitive decline in people at risk of AD, especially those carrying two copies of the APOE 4 gene, which increases the chance of developing AD with symptoms typically starting around age 68. Understanding this link could help treat sleep issues early to potentially slow AD progression. Participants diagnosed with mild Alzheimers disease will undergo various assessments over two years. Sleep patterns will be studied using polysomnography for 24 hours at the start and after 24 months, alongside 14-day actimetrics measurements. Neuropsychological evaluations and sleep-related questionnaires will be completed at inclusion, 12 months, and 24 months. Blood and cerebrospinal fluid samples will be taken to analyze Alzheimer-related biomarkers like A42, A40, Tau, and P-Tau. During the study, participants will have regular visits for cognitive testing and sleep monitoring. Researchers will track changes in cognitive function using the Alzheimers Disease Cooperative Study - Preclinical Alzheimer Cognitive ADCS-PACC scale from inclusion through 24 months. Sleep stages and breathing during sleep will be measured by polysomnography. The study includes safety and cognitive assessments, requiring participants to have a family caregiver to assist with questionnaires and diaries, and last for up to 24 months.

Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease